Stockscreener 앱 받기
1.99%
시간 외 거래:
전일 마감가:
$3.52
열려 있는:
$3.51
하루 거래량:
2.30M
Relative Volume:
0.43
시가총액:
$279.82M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.1037
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-4.43%
1개월 성능:
-24.67%
6개월 성능:
-48.20%
1년 성능:
-45.50%
1일 변동 폭
$3.43
$3.555
1주일 범위
$3.43
$3.74
52주 변동 폭
$2.90
$11.16
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.45 | 291.99M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Can Altimmune Inc. recover in the next quarterWeekly Chart Watchlist with Trade Guidance - Newser
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - Defense World
Securities Fraud Class Action Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Reminds Investors of October 6, 2025 - ACCESS Newswire
Volatility clustering patterns for Altimmune Inc.Free Scalable Portfolio Growth Suggestions - Newser
Predicting Altimmune Inc. trend using moving averagesMachine Learning Intraday Signal Forecast - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
Altimmune's Securities Fraud Litigation: A Cautionary Tale for Biotech Investors - AInvest
Faruqi & Faruqi investigates Altimmune securities class action lawsuit. - AInvest
ALT Investors Have the Opportunity to Lead the Altimmune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
Combining price and volume data for Altimmune Inc.Free Buy Signal Based on Chart Analysis - Newser
Securities Fraud and Market Volatility: The Altimmune Case and Its Lessons for Biopharma Investors - AInvest
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - MarketScreener
Altimmune Inc. stock momentum explainedAI Powered Buy Point Forecast Planner - Newser
Heatmap analysis for Altimmune Inc. and competitorsSmart Entry Signals for Active Traders - Newser
Altimmune Inc. stock daily chart insightsReliable Setup Screener with Low Risk - Newser
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - PR Newswire
Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
Altimmune, Inc. (ALT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
ALT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact The Gross Law Firm - MarketScreener
Shareholders Filed a Lawsuit Against Altimmune for Misleading Clinical Trial Disclosures - TradingView
Altimmune ($ALT) Misleading Pemvidutide Trial Results and Fibrosis Endpoint Failure Case - TradingView
Applying chart zones and confluence areas to Altimmune Inc.Market Opportunity Tracker for Swing Traders - Newser
Order flow analysis tools used on Altimmune Inc.Free Earnings Play Trade Plan With Alerts - Newser
Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit - GlobeNewswire
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investor Alert: Deadline Approaching to Join Altimmune, Inc. (ALT) Class ActionContact Levi & Korsinsky - Newsfile
Altimmune, Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Altimmune Faces Legal Storm as Trial Results Disappoint - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Morningstar
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - cnhinews.com
Analyzing recovery setups for Altimmune Inc. investorsEntry and Exit Strategy for Swing Traders - Newser
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Altimmune, Inc. Securities and Sets a Lead Plaintiff Deadline of October 6, 2025 - Business Upturn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
What makes Altimmune Inc. stock attractive to long term investorsFree Triple Return Setup with Risk Control - Newser
Altimmune reports Q2 2025 financial results on August 12. - AInvest
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | ALT Stock News - GuruFocus
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - The Manila Times
Why Altimmune Inc. stock attracts strong analyst attentionFree Weekly Return Pick Forecast Reports - Newser
Levi & Korsinsky Investigates Altimmune, Inc. (ALT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Market reaction to Altimmune Inc.’s recent newsTechnical Insight Guide for Safer Trades - Newser
Published on: 2025-08-04 04:35:56 - Newser
Should I hold or sell Altimmune Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What are Altimmune Inc. company’s key revenue driversExtraordinary profit generation - Jammu Links News
Does Altimmune Inc. stock perform well during market downturnsRapid portfolio appreciation - Jammu Links News
What makes Altimmune Inc. stock price move sharplyCapitalize on high-growth stocks early - Jammu Links News
Is Altimmune Inc. a good long term investmentDynamic profit opportunities - Jammu Links News
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):